{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["13(9)"],"submitter":["Ain QT"],"pubmed_abstract":["<b>Background:</b> Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, improves outcomes in heart failure (HF) patients, yet inter-individual variability in response remains unclear. Genetic variants in Brain-Derived Neurotrophic Factor <i>BDNF</i> (rs6265) and ATPase Sarcoplasmic/Endoplasmic Reticulum Ca<sup>2+</sup> Transporting 2 ATP2A2 (rs1860561) may influence the treatment efficacy. <b>Objective:</b> To assess the association of <i>BDNF</i> and <i>ATP2A2</i> polymorphisms with the response to low-dose empagliflozin (10 mg) in Pakistani patients with heart failure and a reduced ejection fraction (HFrEF). <b>Methods:</b> In this prospective study, 120 HF patients with an ejection fraction of 25-45% who had been on stable standard heart failure therapy for at least 3 mont"],"journal":["Biomedicines"],"pagination":["2095"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12467674"],"repository":["biostudies-literature"],"pubmed_title":["Personalized Response to Empagliflozin in Heart Failure: Association of BDNF and ATP2A2 Variants in a South Asian Cohort."],"pmcid":["PMC12467674"],"pubmed_authors":["Hasan A","Khan AA","Ahmed S","Azam F","Usman M","Ain QT","Ijaz U","Ahmed R","Ali M","Shaheen A","Ahmed M"],"additional_accession":[]},"is_claimable":false,"name":"Personalized Response to Empagliflozin in Heart Failure: Association of BDNF and ATP2A2 Variants in a South Asian Cohort.","description":"<b>Background:</b> Empagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, improves outcomes in heart failure (HF) patients, yet inter-individual variability in response remains unclear. Genetic variants in Brain-Derived Neurotrophic Factor <i>BDNF</i> (rs6265) and ATPase Sarcoplasmic/Endoplasmic Reticulum Ca<sup>2+</sup> Transporting 2 ATP2A2 (rs1860561) may influence the treatment efficacy. <b>Objective:</b> To assess the association of <i>BDNF</i> and <i>ATP2A2</i> polymorphisms with the response to low-dose empagliflozin (10 mg) in Pakistani patients with heart failure and a reduced ejection fraction (HFrEF). <b>Methods:</b> In this prospective study, 120 HF patients with an ejection fraction of 25-45% who had been on stable standard heart failure therapy for at least 3 mont","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Aug","modification":"2026-06-30T03:24:08.686Z","creation":"2026-06-30T03:16:37.13Z"},"accession":"S-EPMC12467674","cross_references":{"pubmed":["41007658"],"doi":["10.3390/biomedicines13092095"]}}